SubsidieMeestersAPAC – the first targeted therapy for peripheral arterial occlusive disease.
Aplagon is developing APAC, a targeted therapy for advanced peripheral arterial occlusive disease, aiming to improve safety and efficacy in clinical studies to address high morbidity and mortality rates.
Projectdetails
Introduction
There is a major unmet need for effective and safe therapies for advanced peripheral arterial occlusive disease (PAOD) due to the high cardiovascular mortality, morbidity, and amputation rates in these patients.
Product Development
Aplagon is developing the first vascular injury-targeting product (APAC) for the local treatment of advanced PAOD. PAOD is caused by fatty deposits in lower limb arteries (atherosclerosis) that become inflamed (thromboinflammation), resulting in blood coagulation (atherothrombosis).
Mechanism of Action
APAC uniquely targets these vessels, prevents further atherosclerosis, and downregulates thromboinflammation, the main drivers of PAOD.
Progress and Support
Aplagon has completed preclinical proof-of-concept and toxicology studies and received regulatory approval to enter clinical studies. Aplagon has an experienced, international team and is supported by a renowned scientific advisory board.
Funding Application
We are applying for EIC funding to show the safety and efficacy of APAC in PAOD/CLI patients, a major value inflection point.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.099.387 |
| Totale projectbegroting | € 2.999.125 |
Tijdlijn
| Startdatum | 1-9-2022 |
| Einddatum | 28-2-2025 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- APLAGON OYpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
ApTOLL: An innovative neuroprotectant to reduce brain damage in Acute Ischemic Stroke (AIS)The project aims to conduct a Phase 2b trial of ApTOLL, a novel neuroprotectant for acute ischemic stroke, to reduce brain damage and improve outcomes, targeting a multi-billion euro market. | EIC Accelerator | € 2.498.816 | 2024 | Details |
A disruptive hypoxia activated prodrug for the treatment of resistant cancers: an AI-driven approachTUMAGOSTIC aims to advance CP-506, a targeted Hypoxia Activated Prodrug, through clinical trials to improve cancer treatment efficacy and patient outcomes, with commercialization potential exceeding €450M. | EIC Accelerator | € 2.462.533 | 2024 | Details |
PAH-ADVANCE: Accelerating the Clinical Path of NTP42, a disease-modifying drug that will disrupt the future treatment of cardiopulmonary diseases, including pulmonary arterial hypertension (PAH).ATXA Therapeutics aims to advance NTP42, a novel drug for pulmonary arterial hypertension, through Phase II trials and licensing to accelerate market entry and diversify its drug portfolio. | EIC Accelerator | € 2.500.000 | 2023 | Details |
Development of the first oral disease-modifying treatment for chronic obstructive pulmonary disease (COPD)Palobiofarma aims to develop PBF-680, a first-in-class adenosine receptor antagonist, to treat COPD, targeting disease progression and seeking €30M for further clinical trials. | EIC Accelerator | € 2.476.106 | 2022 | Details |
Revolutionary vascular repair patch to treat aortic dissectionsAortyx's biomimetic bioresorbable adhesive patch aims to treat aortic dissections via endovascular deployment, enhancing natural repair and reducing mortality compared to traditional stents. | EIC Accelerator | € 2.500.000 | 2022 | Details |
ApTOLL: An innovative neuroprotectant to reduce brain damage in Acute Ischemic Stroke (AIS)
The project aims to conduct a Phase 2b trial of ApTOLL, a novel neuroprotectant for acute ischemic stroke, to reduce brain damage and improve outcomes, targeting a multi-billion euro market.
A disruptive hypoxia activated prodrug for the treatment of resistant cancers: an AI-driven approach
TUMAGOSTIC aims to advance CP-506, a targeted Hypoxia Activated Prodrug, through clinical trials to improve cancer treatment efficacy and patient outcomes, with commercialization potential exceeding €450M.
PAH-ADVANCE: Accelerating the Clinical Path of NTP42, a disease-modifying drug that will disrupt the future treatment of cardiopulmonary diseases, including pulmonary arterial hypertension (PAH).
ATXA Therapeutics aims to advance NTP42, a novel drug for pulmonary arterial hypertension, through Phase II trials and licensing to accelerate market entry and diversify its drug portfolio.
Development of the first oral disease-modifying treatment for chronic obstructive pulmonary disease (COPD)
Palobiofarma aims to develop PBF-680, a first-in-class adenosine receptor antagonist, to treat COPD, targeting disease progression and seeking €30M for further clinical trials.
Revolutionary vascular repair patch to treat aortic dissections
Aortyx's biomimetic bioresorbable adhesive patch aims to treat aortic dissections via endovascular deployment, enhancing natural repair and reducing mortality compared to traditional stents.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Targeted Protein Degradation as a New Experimental and Therapeutic Approach for Pancreatic Ductal AdenocarcinomaPROTAC-PDAC aims to develop targeted PROTAC therapies to degrade key oncogenic transcription factors in pancreatic cancer, enhancing treatment efficacy while minimizing toxicity. | ERC Consolid... | € 1.999.401 | 2023 | Details |
Pushing Boundaries in Pre-clinical Aortopathy ResearchThis project aims to unravel mechanisms of syndromic thoracic aortic aneurysm and develop effective therapies using patient-derived aorta-on-a-chip models for pre-clinical research. | ERC Starting... | € 1.494.848 | 2024 | Details |
A novel, first-in-its-kind, aptamer-based LYTACs to address the unmet clinical need of diabetic wounds.APTADEGRAD aims to demonstrate the efficacy of novel aptamer-based LYTACs in healing diabetic foot ulcers by targeting key inflammatory proteins to improve treatment outcomes. | EIC Pathfinder | € 2.321.677 | 2022 | Details |
Human Antibody-enabled Cardiovascular Personalized TheranosisABCardionostics aims to develop a multi-marker PET/MRI system using human antibodies to personalize treatment and improve diagnosis of atherosclerosis in vulnerable patients. | EIC Pathfinder | € 3.639.665 | 2024 | Details |
Targeting the Imidazoline I1 receptor as a novel treatment for AtherosclerosisImnovAth aims to develop a novel therapy targeting a microbiota-derived metabolite to enhance atherosclerosis treatment efficacy and advance towards clinical trials and commercialization. | ERC Proof of... | € 150.000 | 2024 | Details |
Targeted Protein Degradation as a New Experimental and Therapeutic Approach for Pancreatic Ductal Adenocarcinoma
PROTAC-PDAC aims to develop targeted PROTAC therapies to degrade key oncogenic transcription factors in pancreatic cancer, enhancing treatment efficacy while minimizing toxicity.
Pushing Boundaries in Pre-clinical Aortopathy Research
This project aims to unravel mechanisms of syndromic thoracic aortic aneurysm and develop effective therapies using patient-derived aorta-on-a-chip models for pre-clinical research.
A novel, first-in-its-kind, aptamer-based LYTACs to address the unmet clinical need of diabetic wounds.
APTADEGRAD aims to demonstrate the efficacy of novel aptamer-based LYTACs in healing diabetic foot ulcers by targeting key inflammatory proteins to improve treatment outcomes.
Human Antibody-enabled Cardiovascular Personalized Theranosis
ABCardionostics aims to develop a multi-marker PET/MRI system using human antibodies to personalize treatment and improve diagnosis of atherosclerosis in vulnerable patients.
Targeting the Imidazoline I1 receptor as a novel treatment for Atherosclerosis
ImnovAth aims to develop a novel therapy targeting a microbiota-derived metabolite to enhance atherosclerosis treatment efficacy and advance towards clinical trials and commercialization.